RxDoctor Payments Data

Eric Hsi, MD

Anatomic Pathology · Rochester, MNNPI 1619934817

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,300 of the $21,106 with a category attached, or 67.8%. 7 manufacturers reported payments, led by Novartis at 37.2% of the total. Reporting peaked in 2022 at $10,172 and has fallen 98.1% since, to $191 in 2023.

$21,106in general payments, 2019–2025

Across 44 payments — averaging $479.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$8K
  • Seagen Inc.$6K
  • Eli Lilly$4K
  • Blueprint Medicines Corporation$2K
  • BD$1K
  • F. Hoffmann-la Roche AG$455
  • plus $205 from 1 others
$263,057in research payments, 2019–2025

Across 6 payments — averaging $43,843 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$263K

What the payments were for

  • Consulting fees$14,30068%
  • Speaking & faculty fees$2,37511%
  • Travel & lodging$3,53817%
  • Food & beverage$8034%
  • Education$910%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis3$7,847
Seagen Inc.19$5,878
Eli Lilly8$3,689
Blueprint Medicines Corporation3$2,011
BD9$1,022
F. Hoffmann-la Roche AG1$455
Abbott1$205

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few anatomic pathology providers in Minnesotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$365,057
Medicare patients
19,612
Services billed
42,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →